Abstract. Five out of six human melanoma cell lines tested were able to degrade in vitro a smooth muscle cell extracellular matrix in a plasmin-dependent way. In three of these five cell lines, this process was mediated by tissue-type plasminogen activator (t-PA) and in the other two cell lines by urokinase-type plasminogen activator (u-PA).
cutaneous inoculation site. The production of plasminogen activators, their inhibitors and urokinase receptor by subcutaneous tumors corresponded with the production by the parental cell lines in vitro.
The two u-PA and PAM producing cell lines showed the highest frequency to form spontaneous lung metastases after subcutaneous inoculation, whereas five of the six cell lines formed lung colonies after intravenous inoculation .
In conclusion, u-PA mediated matrix degradation in vitro and production of u-PA and PAI-1 by human melanoma cell lines correlated with their ability to form spontaneous lung metastasis in nude mice. No correlation was found with the ability to form lung colonies after intravenous injection. These findings suggest a role for u-PA and PAI-1 in a relatively early stage of melanoma metastasis.
are known, the tissue-type (t-PA),' and the urokinase-type (u-PA) . The activity ofthe activators can be regulated by interactions with specific inhibitors, of which two have been described, type 1(PAI-1) and type 2 (PAI-2) (33, 53) . In addition, u-PA and its proenzyme, pro-u-PA, can be localized at cell surfaces by binding through their growth factor domain to a specific receptor (u-PAR) (2, 8, 12, 41, 51, 55, 56, 62) .
To study the role of plasminogen activation system in metastasis ofmalignant melanomas, we have investigated the occurrence of its various components and their mRNA in a set of six human melanoma cell lines with different metastatic behavior in the nude mice. To study the different steps in the metastatic process (primary tumor growth, local invasion and detachment oftumor cells from the primary tumor, lodgement and invasion indistant tissues) the cells were inoculated either subcutaneously or intravenously.
Furthermore, the ability of tumor cells to degrade extracellular matrix produced by smooth muscle cells was used as an in vitro model in which the effects of anticatalytic antibodies against t-PA and u-PA were tested .
Materials and Methods

Cell Lines
All cell lines were derived from human melanoma metastases . The IF6 (59) and MV3 (60) cell lines were developed from lymph node metastases of two different male patients. The BLM cell line is a subline of BRO (35) and was isolated from lung metastases after subcutaneous inoculation of nude mice with BRO cells . The M14 (31) 
Cell Culture
All cell lines were grown as monolayers in DME medium supplemented with 10% FCS, 2 mM glutamine, 100 U/ml penicillin, and 100 pg/ml streptomycin . To determine the protein and mRNA levels of plasminogen activators and their inhibitors fresh serum containing medium was added to the cell cultures shortly before they reached confluency, 24 h later when the cells had reached confluency, the conditioned medium was collected and cell extracts were prepared for antigen determination and RNA isolation .
Assayfor PA and PAIAntigen Antigen levels of t-PA, u-PA, PAW, and PAI-2 were determined in both conditioned media and cell extracts (extracted with 0.5% Triton X-100 and scraped with a rubber policeman) of cultured human melanoma cell lines. The antigen levels in tissue extracts of subcutaneous tumors derived from these cell lines after inoculation in nude mice were also determined . Extracts of subcutaneous tumors in nude mice were prepared using 0.1 M Tris. HCl (pH 7.5)/0.1% Tween 80 as a homogenization buffer. The final extracts contained 50 mg tumor tissue/nil . t-PA antigen was determined using the commercial ELISA Imulyse t-PA (Biopool, Umed, Sweden) . u-PA antigen was determined with a sandwich ELISA, described in detail by Binnema et al . (6) . As a standard, either purified t-PA or u-PA was used, which was standardized against the respective International Standard preparations on an activity basis using the specific activities of 500,000 IU/mg t-PA (22) and 100,000 IU/mg u-PA (WHO preparation c66/46) (48) . PAM and PAI-2 antigen were determined using the commercial ELISAs Tmtelize Stripwell PAI-1 and Tintelize PAI-2 (Biopool) . Detection limits for these assays are x+10 ng for t-PA and u-PA, 5 ng for PAI-1 and 2 ng for PAI-2 per ml .
All determinations were performed in duplicate . Serum containing nonconditioned medium was used as control .
mRNA Analysis Cells were washed with PBS at 37°C and lysed in 4 M guanidium thiocyanate, 25 mM sodium citrate, pH 7.5, 0.5% sarkosyl, 0.1 M 2-mercaptoethanol . RNA was isolated according to Chomczynski and Sacchi (11) . The total amount of RNA isolated was determined by measuring the OD26o, assuming that 1 OD260 unit is equivalent to 40 jug RNA.
RNA samples were electrophoresed on a 1.2 % denaturating agarose gel containing 7 .5% formaldehyde and were transferred to a nylon membrane (Hybond N ; Amersham International, Amersham, United Kingdom) using a Vacugene system (Pharmacia, Uppsala, Sweden) . Membranes were hybridized with 32p labeled cDNA fragments in 7 % SDS, 0.5 M NaHPO2, pH 7.2, 10 mM EDTA at 60°C . Blots were routinely washed with 2 x SSC, 1% SDS for 1 h at 60°C (lx SSC = 0.15 M NaCl, 0.015 M sodium citrate) . cDNA fragments were labeled using the random primer method (Multiprime ; Amersham International), with 32P-dCTP (specific activity was "109 cpm/pg DNA) . Autoradiograms were prepared using Kodak XAR-5 films and intensifying screens at -70°C.
The Journal of Cell Biology, Volume 115, 1991 mRNA Quantification mRNA levels were determined as described by Quax et al . (48) using dot blots containing series ofdilutions of in vitro transcripts of t-PA, u-PA, PAI-1 and PAI-2 as standards. These RNA transcripts were made using T7 RNA polymerase (Promega Biotec, Leiden, The Netherlands) . After removal of the DNA templates with RQl DNAse (Promega Biotec), the amounts of RNA transcripts synthesized were determined by measuring OD260 . As an internal standard 0-actin was used .
cDNA Probes
For the hybridization experiments the following cDNA fragments were used as probes : a 1 .9-kb Bg1II fragment of the human t-PA cDNA (61), a 1 .0-kb EcoRI-PstI fragment of the human u-PA cDNA (37), a 1 .2-kb Pstl fragment of the human PAI-1 cDNA (58), a 1 .2-kb EcoRI fragment of the human PAI-2 cDNA, kindly provided by Dr. E. K . O. Kruithof (52) , and a 1 .2-kb Pstl fragment of a hamster 13-actin cDNA, kindly provided by Dr. W. J . Quax (18) .
As a probe for the u-PA receptor mRNA the p-uPAR-1 plasmid containing the complete cDNA for human u-PAR (51) was used after random primer labeling and hybridization performed as described earlier (36) .
ExtracellularMatrix Preparation and Degradation
Bovine smooth muscle cells (kindly provided by Dr. G . Sperti, Hammersmith Hospital, London) were grown to confluency in DME medium supplemented with 10% FCS, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin in 2-cm2 culture dishes . After the cultures had reached confluency and the formation of extracellular matrix was started, the cells were incubated for 4 d with medium containing a [ 3H]amino acid mixture (1 140/ml, Amersham International) . Cells were then lysed using 0.5 % Triton X-100 in PBS and the cytoskeleton was removed by 25 mM ammoniumhydroxide treatment . Unincorporated [ 3H]amino acids were washed from the remaining extracellular matrix using H2 O (twice) and 75% ethanol . Matrices were dried and stored at -20°C until use. Before tumor cells were seeded onto the 3 H-labeled matrices, the latter were soaked with medium for 1 h . For the extracellular matrix degradation assay 10, cells/2-cm' dish were seeded onto the matrix in 10 % FCS containing DME medium or DME medium supplemented with 100 U/ml aprotinin (as plasmin inhibitor) or specific inhibiting antibodies against t-PA (50) or u-PA (6) . Antibody concentrations used were -30 pg/ml for anti-t-PA and 300 Eag/ml for anti-u-PA . Human plasminogen, purified by affinity chromatography as described previously (63) , was added to the medium in all experiments to a final concentration of 0.14 AM . After 2 d, the conditioned medium was removed and the remaining matrix was degraded with 0.25% trypsin (1 h at 37°C) .
[3H]Amino acid release was determined and the 3H release by the tumor cells was expressed as percentage of the total amount of 3 H released (the sum of the release by the cells and by the trypsin treatment), u-PA Receptor Analysis
The presence of u-PAR in the cells was determined essentially according to Nielsen et al . (41) . Tumor cells were grown to confluency in DME medium plus 10% FCS, detached from the culture dishes using a rubber policeman and washed twice with PBS . After a moderate acid treatment (0.05 M glycine, pH 3 .0, 0 .1 M NaCl ; for 3 min at room temperature) to remove the endogenous u-PA from the receptor, cells were lysed in 0.1 M Tris-HCl pH 8 .1, 1% Triton X-114, 10 mM EDTA, 100 U/ml aprotinin, 1 mM PMSF and centrifuged for 10 min at 10,000 g . The supernatant was stored at -20°C. Diisopropylfluorophosphate (DFP)-treated u-PA (5) (kindly provided by Dr. N. Behrendt, Finsen Laboratory, Copenhagen) was radiolabeled using Na-1251 according the Iodogen procedure (Pierce Chemical Co., Rockford, IL) . u-PA receptor was determined in crude cell extracts by incubation of a sample of the cell extract (of "25,000 cells) with 125j labeled DFP treated u-PA, with or without addition of a 100-fold excess of unlabeled u-PA, in 20 Al PBS, 0 .1% Tween 80 for 1 h at 4°C, followed by incubation with the crosslinking agent disuccinimidyl suberate (2 mM) for 15 min at room temperature and with ammonium acetate (10 mM) for 10 min at room temperature . The samples were then analyzed by SDS-PAGE and autoradiography using Kodak XAR5 film and intensifying screens at -70°C . Extracts of subcutaneous tumor tissue (50 mg/ml) were prepared by homogenization in 0.2 M Tris-HCI (pH 7.5) . Subsequently, membrane fractions were purified by centrifugation of the extracts in an airfuge (Beckman Instruments, Fullerton, CA) at 130,000 g for 15 min . The pellet was resuspended in glycine buffer (0.05 M glycine, pH 3 .0, 0.1 M NaCI), centri-fuged for 15 min at 130,000 g, resuspended in 0.1 M Tris-HCI pH 8.1, 1% Triton X-114, 10 mM EDTA, 100 U/ml aprotinin, 1 mM PMSF, and finally centrifuged for 10 min at 10,000 g. Analysis for presence of u-PAR in the supernatant was performed as described above.
Nude Mice
Balb/c athymic nude mice (nu/nu) were purchased from the Laboratory Breeding Research Center (GI. Bomholtgaard, Ry, Denmark) and kept in separate rooms in cages coveredwith air filters under SPF conditions . Mice were used when 4-6 wk old and were sex matched.
7lumor Cell Inoculation Melanoma cells were harvested from subconfluent cultures by trypsinization, washed twice with serum containing medium, suspended in PBS (1-2 x 107 cells/ml) and inoculated (a) subcutaneously into the lateral thoracic wall to produce tumors at the inoculation site and to produce pulmonary metastases or (b) intravenously into thelateral tail vein to produce lung colonies. 1-2 x 106 Tumor cells were injected in both cases. Mice were routinely checked twice a week and killed when signs of illness were noted or, when they remained healthy, 3-4 mo after inoculation autopsy was performed and kidney, spleen, liver, lymph nodes, and lungs were routinely examined for metastasis both macroscopically and microscopically. Tissue samples from subcutaneous tumors and from thelungs were snap frozen and stored at -70°C forbiochemical analysis and immunohistological staining .
Detection of Lung Metastases
At autopsy, lungs were taken for histopathological examination, fixed in formalin, and embedded in paraffin. To avoid missing micrometastases, 4-,um hematoxylin-and eosin-stained sections from at least three different levels were examined for the presence of lung metastases (59, 60) .
Immunohistochemical Staining of u-PA Indirect immunoperoxidase staining was done with two well-characterized polyclonal rabbit antibodies against human u-PA of different origins (6, 32) on 4-Am frozen sections of xenograft lesions of all six melanoma cell lines. After acetone fixation, sections were processedas described by Nakane and Pierce (40) . As the second antibody, swine-anti-rabbit IgG conjugated to horseradish peroxidase (Dakopatts, Denmark) was used and 3-amino-9-ethylcarbazole was used as a substrate. Harris hematoxylin (Merck, Darmstadt, Germany) was used to counterstain. As a control for specificity of the humanu-PA antibodies rabbit nonimmune serum or antibodies absorbed with purified human u-PA were used (26) .
Results Extracellular Matrix Degradation In Vitro
The capacity of all six melanoma cell lines to degrade extracellular matrix was tested by culturing them on 3H-labeled extracellular matrix produced by bovine smooth muscle cells. Five of the six cell lines had the capacity to degrade the matrix (Fig. 1) . Only Mel 57 showed no significant degradation of the matrix when compared to the background . In all cell lines studied, except Mel 57, matrix degradation could be inhibited almost completely by aprotinin addition (Fig . 1) , indicating the involvement of trypsinlike proteases, probably plasmin, since there was a strong decrease in the matrix degradation when several cell lines were grown in the absence of plasminogen (serum free conditions without addition ofplasminogen) (results not shown) .
Cultivation in the presence of specific antibodies against t-PA showed a clear decrease in the matrix degradation caused by the M14, IF6, and 530 cells, but had no effect on the matrix degradation by the MV3 and BLM cells. Incubation with antibodies against u-PA showed a strong decrease in MV3-and BLM-mediated matrix degradation, but had no by Northern blot hybridizations, using cDNA probes for t-PA, u-PA, PAW, and PAI-2 (Fig . 2) . In all the melanoma cell lines studied t-PA mRNA could be detected, while in only two cell lines, MV3 and BLM, u-PA mRNA was detected . PAI-1 and PAI-2 mRNA were also only detectable in these two latter cell lines. mRNA levels and the correspond- Figure 2 . Northern blot analysis of RNA from different human melanoma cell lines. RNA was isolated as described in Materials and Methods, subjected to electrophoresis and blotted. 10 jig of total RNA was used in each lane . The filters were subsequently hybridized with cDNA fragments of human t-PA, human u-PA, human PAW and human PAI-2. /3-actin was used as a control.
ing protein levels were quantified in cell extracts and in conditioned media in parallel cultures (Table 1) . t-PA antigen was detected in all melanoma cell lines studied and >96 of the t-PA was found in the culture medium after 24 h incubation . u-PA was only detectable in MV3 and BLM . In this case, however, a significant fraction (16 and 30%, respectively) was cell associated after 24 h incubation . PAW antigen was detected in the MV3 and BLM cell lines only and >97 % was found in the culture medium . The highest levels of PAI-2 were detected in MV3 and BLM, but also in the other melanoma cell lines small amounts of PAI-2 were detectable although no mRNA could be detected . In all cases PAI-2 was mainly in a cell-associated form. In general, the mRNA levels correspond well with the protein levels .
Urokinase Cross-Linking to Cell Lysates
Radiolabeled DFP-treated urokinase was incubated and crosslinked with lysates of all six melanoma cell lines studied . In all cell lines, a 94-kD complex was detected after SDS-PAGE and autoradiography. The intensity of the 94-kD band was similar in all the cell lines except Me157, which showed considerably less complex formation (Fig . 3) . In all cases complex formation could be prevented almost completely by addition of excess of unlabeled urokinase . These results indicate that 'III-u-PA binding is saturable and that the complexes formed have characteristics similar to u-PA/u-PAR complexes formed observed with other human cell lines (41) .
Urokinase Receptor mRNA Analysis RNA extracts of all melanoma cell lines were analyzed for Lysates of human melanoma cell lines were incubated with I'll DFP u-PA in the presence (+) or absence (-) of a 100-fold excess of unlabeled u-PA . As described in Materials and Methods, lysates of ti2 .5 x 104 cells were used for each lane. After crosslinking with disuccinimidyl suberate, samples were analyzed using SDS-PAGE and visualized using autoradiography.
the presence of the u-PAR mRNA using Northern blot hybridization with a specific u-PAR cDNA probe (51) . In all the cell lines u-PAR mRNA was detectable (Fig. 4) , however the intensity of the hybridization signals varied considerably. The strongest signal was found in RNA extracts from the MV3 and BLM cells .
Tumorigenicity and Metastatic Behavior ofMelanoma Cell Lines
To assess the tumorigenicity in nude mice, melanoma cells were injected subcutaneously. The data concerning tumor formation at the site of inoculation (tumor take) are presented Fig. 5 , subcutaneous xenografts of IF6 were encapsulated by host stroma (Fig.  5 , A and C), while MV3 (and BLM) cells were not (Fig. 5  B) . In addition, MV3 (and BLM) cells invaded into the subdermal muscles (Fig. 5 D) . As it appears from Table II , the number of lesions found in the lungs of mice that developed metastases varied strongly and both tumor cell emboli (Fig.  5 E) and invasively growing lung metastases (Fig. 5 F) were observed. The capacity to develop experimental metastases after intravenous tumor cell inoculation was investigated in another experiment and presented in Table II , right. All melanoma cell lines, except IF6, had the capacity to colonize to the lung and form metastases with frequencies between 50 (M14) and 95% (MV3) of mice injected .
Detection ofPlasminogen Activator and Inhibitor in Tumor Extracts
Antigen levels in extracts of subcutaneous tumors were determined for t-PA, u-PA and PAW (Table IIn . Similar to the results obtained with the corresponding cultivated cells (see Table I ), all tumors contained t-PA while u-PA and PAI-1 only were detected in those deriving from the MV3 and BLM cell lines .
Extracts of subcutaneous tumors were also analyzed for the occurrence of u-PA receptor by cross-linking with 'IIIlabeled DFP-treated u-PA. In all tumor extracts studied, except in Me157, 94-kD complexes could be detected, although at a low level (Fig. 6) . After acid treatment ofthe membrane fraction ofthe tumor extracts (a procedure which dissociates endogenous u-PA from its receptor), a strong increase in the complex formation in the MV3 and BLM tumor extracts could be detected (Fig. 6 ) . This indicates that receptors were present in all the tumors except Mel 57, that the levels of u-PAR in MV3 and BLM tumors were higher than in the tumors of the other cell lines, and that in these two tumors most of the urokinase receptors were occupied by u-PA, which because of a species specificity in the receptor binding (2, 21) must be of human origin .
Immunohistochemical Localization ofu-PA in Tumors
To confirm the presence ofu-PA in the tumors caused by the melanoma cell lines MV3 and BLM, sections of xenograft lesions were stained immunohistologically using two different u-PAspecific polyclonal antibodies. For both antibodies similar results were obtained. Fig . 7 , a and c shows that BLM cells both in the subcutaneous tumor and in lung metastases derived from these tumors showed a strong, evenly distributed, u-PA staining . For MV3 a similar staining pattern was observed (data not shown) . No u-PA staining was detected in the xenografts of any of the other four cell lines studied (Fig. 7 b) .
Discussion
It is found that five of the six human melanoma cell lines tested were able to digest in vitro an extracellular matrix synthesized by bovine smooth muscle cells in a largely plasmindependent way. Degradation of the extracellular matrix was markedly inhibitedby antibodies against either t-PA or u-PA. Moreover, it was blocked nearly completely by addition of aprotinin to the culture medium, which contained serum and additional plasminogen . These results suggest that plasmin is involved in the matrix degradation . As the extracellular matrices were produced by smooth muscle cells without ad- dition of ascorbic acid to the culture medium they contain little or no collagen (10, 29, 30) . The matrix degradation was mediated virtually only by t-PA in three of the cell lines (M14, IF6, and 530) while in two cell lines (BLM and MV3) it was mediated virtually only by u-PA (Fig . 1) . Very little, although significant matrix degradation was observed with Mel57 cells . This matrix degradation could not be inhibited by antibodies to u-PA or t-PA and could only partly (50%) be inhibited by aprotinin . The finding that u-PA can mediate degradation of extracellular matrix in this system is in agreement with a previous report by Cajot et al . (10) , in which mouse L-cells transformed with the human u-PA gene were studied. All melanoma cell lines studied produced large quantities of t-PA mRNA and antigen, which was mainly secreted into Figure 6 . Analysis for u-PA receptor in extracts of subcutaneous tumors derived from human melanoma cell lines (A) or isolated, acid treated, membrane fractions (B) were incubated with 'III DFP u-PA . After crosslinking with disuccinimidylsuberate, samples were analyzed using SDS-PAGE and visualized using autoradiography. Lysates of U937 cells were used as a positive control .
the medium (Table 1) . u-PA mRNA and protein, however, were only detected in those cell lines, showing u-PA mediated matrix degradation : BLM and MV3 . These were also the only cell lines producing large quantities of PAM mRNA and protein and were also the cells with the highest PAI-2 mRNA and protein content, although PAI-2 protein was detected in small amounts in all cell lines . u-PA was in the MV3 and BLM cells partly found in a cell-associated form (Table  I ) . This portion of urokinase can either be located intracellularly or at the cell surface, specifically bound to the urokinase receptor (31, 45, 46, 55, 62) . The presence of a specific u-PA receptor in all the melanoma cell cultures was demonstrated by cross-linking experiments with 125 1 labeled DFP-treated urokinase. Urokinase receptor mRNA was also detectable in all the melanoma cells studied . The u-PAR mRNA analysis showed the strongest signals for MV3 and BLM . An interesting observation is that although all cell lines produce t-PA, matrix degradation caused by the MV3 and BLM cells could not be inhibited by anti-t-PA while antiu-PA inhibited the matrix degradation markedly. A possible explanation might be inhibition of t-PA by PAM, in contrast u-PA in the medium is probably unaffected by PAM because it is mainly present in its proenzyme form (1) . Receptorbound u-PA can be inhibited by PAM (13) but the cell surface pathway of u-PA catalyzed plasminogen activation may still be efficient in the degradation of the extracellular matrix due to (a) a different location of u-PA and PAM, as it has been observed in some cell types (45) ; (b) the enhancement of plasmin formation caused by concomitant binding or prou-PA and plasminogen to cell surfaces (19, 54) ; (c) a protection of surface-bound plasmin from its serum inhibitor azantiplasmin (44, 54) ; and (d) high local concentrations of plasmin at the interphase between the cells and the matrix .
All the human melanoma cell lines could to some extent Figure 7 Immunohistochemical staining of tumors for u-PA . Primary tumors obtained by subcutaneous inoculation of (A) BLM cells and (B) Mel 57 cells and (C) a lung metastasis produced after subcutaneous inoculation of BLM cells . Frozen sections were stained with polyclonal rabbit anti-human-u-PA antibody (56) as described, with nuclear counterstaining . No staining was obtained with the antibody after absorption with purified human u-PA (26) . Staining with a different polyclonal rabbit anti-human-u-PA antibody (32) gave identical stain . Bar, 1 um .
produce subcutaneous tumors at the site of inoculation . Since human melanoma cell lines were used in mice it was possible to study the expression of t-PA, u-PA, and PAW by the tumor and the metastases in vivo in the mouse tissue, using species specific antibodies . The expression of human t-PA, u-PA, and PAI-1 in these tumors in vivo corresponded well with the expression in vitro. t-PA was found in extracts of all the tumors, while u-PA and PAW was found only in the MV3 and BLM tumors . The presence of u-PA in the MV3 and BLM tumors and its absence in the other tumors was confirmed by the immunohistochemical studies . No mouse u-PA could be detected in the tumors (not shown) . In extracts of all the subcutaneous tumors, except the Mel 57-derived tumor, u-PAR was detectable. After mild acid treatment, u-PA binding to lysates of the MV3 and BLM tumors increased dramatically, indicating that in these two cases the receptor was already largely occupied by u-PA produced by the human tumor cells, because the human urokinase receptor can not efficiently bind mouse u-PA (2, 21) .
Out of the six cell lines only MV3 and BLM frequently developed lung metastases . These two cell lines were also the only ones having u-PA mediated matrix degradation in vitro and u-PA and PAI-1 production in vitro and in vivo . The melanoma cell lines that only produce t-PA did not, or only sporadically, develop lung metastases after subcutaneous inoculation . The cells forming metastasis sporadically, Me157 and M14, might use other proteolytic enzymes . Matrix degradation experiments with Me157 reveal no inhibition by antibodies against t-PA and u-PA and only a very limited effect of aprotinin, suggesting the involvement of non-serine proteases . These observations suggest a correlation between u-PA production, PAI-1 production and frequent spontaneous metastasis after subcutaneous inoculation . Statistical analysis reveals that there is only a 0.5-7% probability that this correlation is based on chance, depending on the fact whether u-PA and PAW production are completely independent or strictly coupled .
All the human melanoma cell lines, except IF6, caused lung colonies in at least 49 % of the mice when inoculated intravenously in the tail vein (Table II B ) . The differences in metastasis formation after subcutaneous versus intravenous inoculation suggests that u-PA and/or PAI are involved especially in the early steps in the metastatic cascade and not in the lodgement of melanoma cells in the lung. This conclusion is in contrast to previous reports in which a role of plasminogen activators in formation oflung colonies after intravenous inoculation of tumor cells was suggested in studies with transfection of t-PA and u-PA genes (3) or with inhibition of u-PA by preincubation with anti-catalytic u-PA antibodies (27) .
Our findings suggest that the ability to metastasize after subcutaneous inoculation is not only related to u-PA production but possibly also to the production of PAW and PAI-2 . In some cell types receptor-bound pro-u-PA and u-PA is localized to cell-cell and focal-cell substratum contact sites (28, 45, 46, 54) , and it has been proposed that a selective activation of pro-u-PA on some of these contact sites may lead to a directional proteolysis involved in cell migration (46, 17) . A similar role might also be played by t-PA when it occurs in a surface bound form (7) . PAI-1 and PAI-2 are effective inhibitors of u-PA even when it is receptor bound (4, 13, 14, 20, 47) and it is possible that the inhibitors are required
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